Loading…
Emergent BioSolutions Inc. is projected to rise to $8.61 by 2027, a +7% move from its current price of $8.05. EBS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $7.85 | $8.05 | $8.26 | +0.03% |
| Jul 14 | $7.77 | $8.06 | $8.35 | +0.06% |
| Jul 15 | $7.70 | $8.06 | $8.43 | +0.09% |
| Jul 16 | $7.65 | $8.06 | $8.49 | +0.13% |
| Jul 17 | $7.61 | $8.06 | $8.54 | +0.16% |
| Jul 18 | $7.57 | $8.07 | $8.59 | +0.19% |
| Jul 19 | $7.53 | $8.07 | $8.64 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.53 | $8.07 | $8.64 | +0.22% |
| Week 2 | $7.34 | $8.09 | $8.91 | +0.44% |
| Week 3 | $7.20 | $8.10 | $9.12 | +0.66% |
| Week 4 | $7.08 | $8.12 | $9.31 | +0.88% |
| Week 5 | $6.99 | $8.14 | $9.48 | +1.10% |
| Week 6 | $6.90 | $8.16 | $9.64 | +1.33% |
| Week 7 | $6.82 | $8.17 | $9.80 | +1.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Emergent BioSolutions Inc. is a life sciences company that provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services.
Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions Inc. (EBS) is a healthcare company whose stock trades around $8.53 per share and carries a market capitalization of $440.12M. It ranks 3144 by market cap in its universe. The current price sits near key near-term indicators, and the forecast suggests a path from around the current level toward higher prices over the next several years.
A major floor 14.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 14.0% above — a clean break opens room to run.
A major ceiling 21.2% above — clearing it would confirm fresh momentum.
Key EBS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EBS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.17 | Sell | $8.16 | Sell |
| MA 10 | $8.28 | Sell | $8.20 | Sell |
| MA 20 | $8.20 | Sell | $8.22 | Sell |
| MA 50 | $8.38 | Sell | $8.36 | Sell |
| MA 100 | $8.54 | Sell | $8.71 | Sell |
| MA 200 | $9.73 | Sell | $8.93 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.93 | Neutral |
| Stoch RSI (14) | 26.84 | Neutral |
| CCI (20) | -57.96 | Neutral |
| Williams %R (14) | -70.59 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 0.50 | Buy |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 29.41 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 34.11 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 8.11 | Sell |
| ADX (14) | 6.68 | Neutral |
| ATR (14) | 0.19 | Info |
The near-term technical picture is neutral. The RSI(14) is 50, and the 50-day simple moving average is $8.38, while the 200-day simple moving average sits at $9.72. Support is seen at $7.75 and resistance at $9.18, with a 30-day price range of $6.95 to $10.47. The stock exhibits elevated volatility, with annualized volatility at 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.75 | $8.05 | $10.39 | 0% | Neutral | |
| $6.89 | $8.61 | $11.36 | +7% | Neutral | |
| $8.04 | $10.31 | $14.10 | +28% | Bullish | |
| $9.67 | $12.68 | $17.83 | +58% | Bullish | |
| $10.08 | $13.47 | $19.38 | +67% | Bullish | |
| $10.59 | $14.41 | $21.15 | +79% | Bullish | |
| $10.56 | $14.60 | $21.83 | +81% | Bullish | |
| $10.96 | $15.38 | $23.38 | +91% | Bullish | |
| $12.54 | $17.85 | $27.55 | +122% | Bullish | |
| $13.71 | $19.80 | $30.99 | +146% | Bullish | |
| $17.63 | $27.09 | $44.99 | +236% | Bullish | |
| $31.21 | $53.34 | $96.63 | +563% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.75 | $8.05 | $9.76 | +0.00% |
| August 2026 | $6.94 | $8.18 | $9.89 | +1.57% |
| September 2026 | $6.98 | $8.28 | $10.12 | +1.31% |
| October 2026 | $7.20 | $8.59 | $10.60 | +3.76% |
| November 2026 | $7.15 | $8.57 | $10.64 | -0.30% |
| December 2026 | $6.90 | $8.31 | $10.39 | -3.04% |
Click any year to see its month-by-month EBS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, EBS is projected to trade between $7.75 and $10.39, averaging $8.05 — a potential gain of 0% from today's $8.05. A consolidation phase looks the most probable path here.
Emergent BioSolutions Inc.'s 2027 outlook centres on $8.61, within a $6.89 to $11.36 range. That is up +7% on the projected 2026 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2028, EBS could reach as high as $14.10, with a base case around $10.31 and support toward $8.04 — roughly +28% from $8.05. Buyers look set to stay in control over this stretch.
Expect EBS to range from $9.67 to $17.83 through 2029. The $12.68 average target implies a +58% move from current prices. That is up +23% on the projected 2028 average. Momentum favours further upside here.
The EBS price prediction for 2030 points to an average of $13.47 (low $10.08, high $19.38) — a potential gain of +67% on today's $8.05. Buyers look set to stay in control over this stretch.
In 2031, EBS is projected to trade between $10.59 and $21.15, averaging $14.41 — a potential gain of +79% from today's $8.05. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Emergent BioSolutions Inc.'s 2032 outlook centres on $14.60, within a $10.56 to $21.83 range. That is up +1% on the projected 2031 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, EBS could reach as high as $23.38, with a base case around $15.38 and support toward $10.96 — roughly +91% from $8.05. Momentum favours further upside here.
Expect EBS to range from $12.54 to $27.55 through 2034. The $17.85 average target implies a +122% move from current prices. That is up +16% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The EBS price prediction for 2035 points to an average of $19.80 (low $13.71, high $30.99) — a potential gain of +146% on today's $8.05. Momentum favours further upside here.
In 2040, EBS is projected to trade between $17.63 and $44.99, averaging $27.09 — a potential gain of +236% from today's $8.05. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Emergent BioSolutions Inc.'s 2050 outlook centres on $53.34, within a $31.21 to $96.63 range. That is up +97% on the projected 2040 average. That marks a +563% change versus current levels. Momentum favours further upside here.
Investing $1,000 in EBS today (≈ 124.223602 EBS) could be worth
$6,626.67
+$5,626.67 (+563%) by 2050 · US Dollar
Based on the average projected EBS price of $53.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EBSwould be worth at today's price.
$1,000 invested in EBS on Jul 10, 2025 (≈ 136.425649 EBS) would be worth
$1,098.23
+$98.23 (+9.8%) today · 1.10× · US Dollar
Based on a EBS entry price of $7.33 vs. today's $8.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.28 | $972.22 | -2.8% |
| 1 month ago | $8.24 | $976.94 | -2.3% |
| 3 months ago | $7.96 | $1,011.31 | +1.1% |
| 6 months ago | $12.39 | $649.72 | -35.0% |
| 1 year ago | $7.33 | $1,098.23 | +9.8% |
| All time (5.0y) ago | $57.92 | $138.98 | -86.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EBS forecast.
Our base-case forecast reaches $16.00 around 2034.
Implied market cap at $16.00: $825.54M
The multi-year forecast shows a bullish trajectory after 2026. The 2026 forecast is an average price of $8.53 with 0% ROI. From 2027 onward, the averages rise, with 2027 at $9.12 and an ROI of 7%, 2028 at $10.74 (25.9%), 2029 at $13.68 (60.4%), 2030 at $14.44 (69.3%), and 2031 at $14.93 (75%), continuing through 2032 $15.39 (80.4%), 2033 $16.03 (87.9%), 2034 $18.26 (114.1%), 2035 $21.00 (146.2%), 2040 $27.86 (226.6%), and 2050 $55.08 (545.8%).
The forecast depicts a long-term upside with notable gains by 2040 and 2050, but these are estimates and carry uncertainty and risk due to the price path and volatility.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $14.44, a minimum of $10.44, a maximum of $21.61, and a projected ROI of 69.3%.
The forecast shows a bullish long-term trajectory with averages rising to $55.08 by 2050 and ROIs up to 545.8%. Near term, 2026 shows 0% ROI and 2027 shows 7%, indicating uncertainty and risk alongside potential upside.
Yes. The 2030 max is $21.61, and the 2035 max is $34.61, with a 2040 max of $49.13 and a 2050 max of $107.08.
The near-term picture is neutral. RSI(14) is 50, SMA50 is $8.38, SMA200 is $9.72, with support at $7.75 and resistance at $9.18. The 30-day range is $6.95 to $10.47, and volatility is elevated at 60%.
Current price is $8.53 and market cap is $440.12M, with a rank of 3144.
Emergent BioSolutions Inc. Community Discussion
0Share your Emergent BioSolutions Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.